Lung-moistening and dampness-reducing medicinal and edible composition containing pachymaran and application thereof

Abstract

The invention relates to the technical field of health-care food and medicine, in particular to a pachymaran-containing medicinal and edible composition for moistening lung and reducing dampness and application of the pachymaran-containing medicinal and edible composition. The invention relates to a pachymaran-containing medicinal and edible composition for moistening lung and reducing dampness. The effective components of the composition consist of the following raw materials in parts by weight: 10-25 parts of water-soluble pachymaran and 4-10 parts of a lily extract. The water-soluble pachymaran and the lily extract are innovatively combined, and the obtained composition can relieve cough, enhance immunity, reduce inflammatory response and improve damp evil, so that the effects of moistening lung, relieving cough and improving lung functions are achieved.

Description

Technical Field

[0001] This invention relates to the fields of health food and pharmaceutical technology, and in particular to a medicinal and edible composition containing Poria cocos polysaccharide that moistens the lungs and reduces dampness, and its uses. Background Technology

[0002] Coughing is one of the most common clinical symptoms of respiratory diseases, a protective reflex action triggered by irritation of the respiratory tract. Prolonged, severe coughing can lead to respiratory bleeding, chest pain, and impaired sleep and quality of life; in severe cases, it can cause complications such as emphysema and bronchiectasis. Existing lung-moistening and cough-relieving solutions still have significant shortcomings in terms of efficacy, safety, stability, taste, and patient compliance. There is an urgent need to develop a novel lung-moistening and cough-relieving natural composition derived from both food and medicine that can maintain the synergistic advantages of multiple components in traditional Chinese medicine while possessing the characteristics of modern formulation quality control, good taste, stability, high efficacy, and high safety. Summary of the Invention

[0003] The purpose of this invention is to address the aforementioned shortcomings of the prior art by proposing a lung-moistening and cough-relieving composition containing Poria cocos polysaccharide, which has significant effects in moistening the lungs and relieving cough, high safety, and good palatability, as well as its uses.

[0004] The first objective of this invention is to provide a medicinal and edible composition containing Poria cocos polysaccharide that moistens the lungs and reduces dampness. The effective components of the composition are composed of the following raw materials in parts by weight: water-soluble Poria cocos polysaccharide: 10-25 parts, lily extract: 4-10 parts.

[0005] In this invention, the weight parts can be weight units known in the art such as μg, mg, g, kg, or multiples thereof, such as 1 / 10, 1 / 100, 10 times, 100 times, etc.

[0006] Furthermore, the degree of substitution of water-soluble Poria cocos polysaccharide was determined by copper salt complexometric titration, with an average degree of substitution of 0.6 ± 0.05.

[0007] Further, the water-soluble Poria cocos polysaccharide was prepared as follows: Poria cocos powder was added to ethanol and stirred, then NaOH was added for alkalization, then an etherifying agent was added and heated for etherification, the pH was adjusted to 6-7 with glacial acetic acid, the water-soluble Poria cocos polysaccharide sample was washed with ethanol, and then dried in the sun until its moisture content was less than 7%, and sieved through a 60-100 mesh sieve.

[0008] Furthermore, the mass-to-volume ratio of Poria cocos powder to ethanol is 60-100g:300-500mL; the mass ratio of added NaOH, etherifying agent to Poria cocos powder is 18-30:36-60:60-100.

[0009] Furthermore, the preparation method of lily extract specifically includes the following steps: Lily powder was dissolved in ethanol and extracted using ultrasonic extraction. After completion, centrifuge at room temperature and collect the supernatant, which is the lily extract. The lily extract was concentrated to obtain lily extract concentrate; The concentrated lily extract was freeze-dried to obtain crude lily extract. After enzymatic hydrolysis of crude lily extract, centrifugation was performed, and the supernatant was collected. Sevage reagent was added, and the mixture was shaken, centrifuged, and the supernatant was collected. This process was repeated until no protein layer was observed. The final supernatant was then freeze-dried in a freeze dryer to obtain lily extract.

[0010] The second objective of this invention is to provide the use of the above-mentioned lung-moistening and dampness-reducing composition containing Poria cocos polysaccharide in the preparation of health foods or beverages with lung-moistening, dampness-reducing, lung function-improving, and immune-regulating functions.

[0011] The third objective of this invention is to provide the use of the above-mentioned lung-moistening and dampness-reducing composition containing Poria cocos polysaccharide in the preparation of drugs for moistening the lungs, reducing dampness, improving lung function, and regulating immunity.

[0012] Furthermore, the food-medicine homology composition can be prepared into any suitable oral pharmaceutical formulation by adding excipients as needed.

[0013] Furthermore, the oral dosage form of the drug is granules, tablets, capsules, blister packs, effervescent tablets, powders, oral liquids, or pills.

[0014] Furthermore, the excipients are pharmaceutically acceptable excipients.

[0015] This invention innovatively combines water-soluble Poria cocos polysaccharide and lily extract to obtain a composition that can relieve cough, enhance immunity, reduce inflammatory response, and improve dampness, thereby achieving the effects of moisturizing the lungs, relieving cough, and improving lung function. Attached Figure Description

[0016] Figure 1 Effects of different concentrations (left) / ratios (right) of water-soluble Poria cocos polysaccharide and lily extract on the viability of RAW264.7 cells; Figure 2 The frequency and latency of coughing in mice stimulated by ammonia water; Figure 3 Mouse serum inflammatory factor levels; Figure 4 HE staining of mouse tracheal tissue; Figure 5 HE staining of mouse lung tissue. Detailed Implementation

[0017] The following are specific embodiments of the present invention, which are described in conjunction with the accompanying drawings. However, the present invention is not limited to these embodiments.

[0018] The water-soluble Poria cocos polysaccharide and lily extract used in the examples were prepared using the following method.

[0019] The preparation method of water-soluble Poria cocos polysaccharide specifically includes the following steps: Add 500 mL of ethanol to the reaction vessel, start stirring, slowly add 100 g of Poria cocos powder, and stir for 1 hour; then add 30 g of NaOH for alkalization and react for 1 hour; then add 60 g of sodium chloroacetate as an etherifying agent and heat for etherification for 5 hours, adjust the pH to 7 with glacial acetic acid, wash the water-soluble Poria cocos polysaccharide sample with ethanol, air dry, and finally dry it until the moisture content is less than 7%, and sieve it through a 60-100 mesh sieve.

[0020] The degree of substitution of water-soluble Poria cocos polysaccharide was determined by copper salt complexometric titration, with an average degree of substitution of 0.6 ± 0.05.

[0021] The preparation method of lily extract specifically includes the following steps. Lily extract: Dissolve 5g of lily powder in 60% ethanol at a ratio of 1:20, and extract using ultrasound at 75°C and 180W for 30 min. After extraction, centrifuge at 3000 r / min for 10 min at room temperature, and collect the supernatant, which is the lily extract.

[0022] The lily extract was concentrated in a rotary evaporator at 40 °C to 50 °C to obtain a concentrated lily extract.

[0023] The concentrated lily extract was freeze-dried for 12 hours to obtain crude lily extract.

[0024] Add crude lily extract and distilled water to a 60°C water bath at a ratio of 1:60 and stir thoroughly. Adjust the pH to 6.4 with acetic acid and add papain for enzymatic hydrolysis.

[0025] Centrifuge the enzymatic hydrolysate at 5000 r / min for 5 min at room temperature, collect the supernatant, add Sevage reagent, vortex, centrifuge, collect the supernatant, and repeat the operation until no protein layer is visible.

[0026] The final supernatant was freeze-dried in a freeze dryer to obtain lily extract.

[0027] Example 1 This embodiment provides a food-medicine homology composition, the active ingredients of which are composed of water-soluble Poria cocos polysaccharide and lily extract in a mass ratio of 1:1.

[0028] The above-mentioned food-medicine homology composition was sterilized, and then added to a certain proportion of water and decocted for 5-15 minutes. The proportions of the food-medicine homology composition to water were 0.2, 0.4, 0.6, 0.8, and 1.0 mg / mL, respectively.

[0029] Example 2 This embodiment provides a food-medicine homology composition, the active ingredients of which are composed of water-soluble Poria cocos polysaccharide and lily extract in different mass ratios, namely water-soluble Poria cocos polysaccharide: lily extract in ratios of 5:1, 4:1, 3:1, 2:1, and 1:1.

[0030] The above-mentioned food-medicine homology composition is sterilized, and then added to a certain proportion of water and decocted for 5-15 minutes. The ratio of the food-medicine homology composition to water is 0.6 mg / mL.

[0031] Results after implementation: Cellular experiments: This invention was conducted on RAW264.7 cells (mouse monocytes / macrophages). Macrophages are key initiators of inflammatory responses in the body. When triggered by stimuli such as LPS, macrophages secrete inflammatory factors, regulating the body's inflammatory processes. The results of this cellular-level verification are as follows: Figure 1 As shown in the figure: The normal control group (NC group) maintained near 100% cell viability, indicating normal growth. However, the model group stimulated with lipopolysaccharide (LPS) showed a significant decrease in cell viability, suggesting that LPS successfully induced cell damage. In contrast, the cell viability of the water-soluble Poria cocos polysaccharide and lily extract intervention groups (0.2, 0.4, 0.6, 0.8, 1.0 mg / mL) in Example 1 showed a significant increase with increasing concentration, followed by a decrease. The improvement effects of the 0.4, 0.6, and 0.8 mg / mL groups were statistically significant, with the 0.6 mg / mL concentration showing the best effect. These results indicate that lily extract can effectively alleviate LPS-induced cell damage and enhance cell viability.

[0032] The drug was administered at a concentration of 0.6 mg / mL, and cell viability was detected using MTT assays in different ratios as described in Example 2. The cell viability of the intervention groups (5:1, 4:1, 3:1, 2:1, 1:1) showed a significant increase with increasing lily extract concentration, with the 2:1 group showing the best effect followed by a decrease. Therefore, the 2:1 ratio was selected for mouse experiments.

[0033] Mouse experiment Ammonia can stimulate respiratory receptors and cause coughing. The ammonia-induced cough test is a classic test used to evaluate the antitussive effect of drugs.

[0034] Therefore, this invention uses ammonia atomization to model mice. After KM mice were acclimatized for 5 days, ammonia atomization was used for 60 seconds, and the number of coughs in the mice within 180 seconds was recorded. Coughing mouse models with 50-100 coughs were selected and randomly grouped.

[0035] The model control group (MC), lily extract (250 mg / kg, CC), water-soluble Poria cocos polysaccharide (250 mg / kg, CMP), lily extract + water-soluble Poria cocos polysaccharide compound group (250 mg / kg, CC+CMP), and positive control group were administered pentoxyverine ammonium chloride tablets (20 mg / kg, PC), with 6 mice in each group. A blank control group (NC) was not subjected to ammonia nebulization. The normal group and model group were administered an equal volume of physiological saline by gavage. Gavage was continued for 7 days. One hour after the last administration on day 7, all groups except the normal group were exposed to ammonium hydroxide for 60 seconds, and the number of coughs within 180 seconds was recorded. Two hours later, the mice were sacrificed, and lung and tracheal tissues were collected for HE staining to observe pathological changes in the mouse tissues. Serum levels of inflammatory factors were also measured.

[0036] Cough frequency record and incubation period record like Figure 2 As shown, the NC group had 0 coughs and an average latency of 0 seconds; the MC group had 97 coughs after 60 seconds of ammonia nebulization and an average latency of 30 seconds, significantly higher than the normal group of mice not exposed to ammonia, indicating that ammonia nebulization successfully established a mouse cough model. The PC group had 65 coughs after 60 seconds of ammonia nebulization and an average latency of 46.7 seconds; the CC group had 61 coughs after 60 seconds of ammonia nebulization and an average latency of 42.6 seconds; and the CMP group had 71 coughs after 60 seconds of ammonia nebulization. p The mean latency period (<0.01) was 44 s, significantly lower than the mean latency period (MC); the mean number of coughs in the CC+CMP compound group mice after 60 s ammonia nebulization was 50, and the mean latency period was 50 s, significantly lower than the mean latency period (MC). p <0.01); The above results indicate that the combination of lily extract and water-soluble Poria cocos polysaccharide has an antitussive effect on mice with ammonia-induced cough, and its effect is better than that of the PC group, CC group and CMP group.

[0037] Serum and inflammatory factor detection Interleukin-6 (IL-6) is a multifunctional cytokine that promotes T cell development, stimulates cytotoxic T cell responses, and participates in the cascade amplification of inflammatory responses. Figure 3As shown, the IL-6 levels in the serum and lung tissue homogenates of normal control mice (NC group) were in a low state of basal inflammation; the IL-6 levels in the serum and lung tissue homogenates of model mice (MC group) were significantly increased. p <0.01); IL-6 secretion in the positive control group (PC group) was significantly lower than that in the MC group ( p <0.01 indicates that the positive control drug has a reliable anti-inflammatory effect. Compared with the MC group, the CMP group, CC group, and CC+CMP group treatments all significantly reduced the serum IL-6 level in mice ( p <0.01), among which CC+CMP showed the most significant effect.

[0038] Tumor necrosis factor-α (TNF-α) is an early initiator of the inflammatory response and plays a central role in the formation of the inflammatory microenvironment. In the normal control group (NC group), the serum TNF-α level of mice was at a low level of basal inflammation. In the model group (MC group), the serum and lung tissue homogenate TNF-α levels of mice were significantly increased (p<0.01), while the serum TNF-α level of the positive control group (PC group) was significantly lower than that of the MC group (p<0.01), demonstrating that the positive control drug has a reliable anti-inflammatory effect. Compared with the MC group, treatment with the CMP group, CC group, and CC+CMP group significantly reduced the secretion level of TNF-α in the serum and lung tissue homogenate of mice. Among them, the CC+CMP group had the lowest serum TNF-α secretion level (p<0.01), followed by the CMP group (p<0.01), and then the CC group (p<0.05).

[0039] Interleukin-1β (IL-1β) is a highly potent pro-inflammatory cytokine and a mediator of inflammation. As a major active component of the IL-1 family, it plays a crucial regulatory role in inflammatory immune responses. In the normal control group (NC group), the IL-1β levels in serum and lung tissue homogenates of mice were at a low level of basal inflammation. In the model group (MC group), the IL-1β levels in serum and lung tissue homogenates of mice were significantly increased (p<0.01), further demonstrating that ammonia stimulation can successfully induce an inflammatory response in mice. The IL-1β secretion in the positive control group (PC group) was significantly lower than that in the MC group (p<0.01), demonstrating that the positive control drug has a reliable anti-inflammatory effect. Compared with the MC group, treatment with the CMP group, CC group, and CC+CMP group all significantly reduced the IL-1β levels in mouse serum (p<0.01), and all three groups were close to the PC group, showing good anti-inflammatory effects.

[0040] Pathological observation of mouse tracheal tissue like Figure 4As shown, under a light microscope, the tracheal wall consists of three layers: mucosa, submucosa, and adventitia. The free surface of the mucosa contains neatly arranged columnar ciliated cells. The submucosa contains blood vessels, lymphatic vessels, nerves, and numerous mixed gonads. The cellular composition and structure of the tracheal mucosal epithelium in the NC group mice, without ammonia stimulation, are clear, and the mucosa is intact without congestion. In contrast, the MC group mice, which experienced coughing induced by ammonia stimulation, showed localized sloughing of the tracheal mucosal epithelium, significant submucosal congestion, and a large number of inflammatory cells, indicating a successful establishment of the cough model. The CMP and CC group mice showed significant improvement in the aforementioned lesions, with only a small amount of mucosal epithelial sloughing and inflammatory cells remaining. The tracheal mucosal epithelial cells of mice in the CC+CMP and PC groups were neatly arranged and clearly structured, with only a small number of inflammatory cells. Compared with the tracheal wall structure of normal mice, there was no significant difference. Therefore, it can be concluded that water-soluble Poria cocos polysaccharide, lily extract, and the combination of water-soluble Poria cocos polysaccharide and lily extract can effectively alleviate the local shedding of tracheal mucosal epithelium and submucosal congestion caused by ammonia stimulation in mice. Among them, the combination of water-soluble Poria cocos polysaccharide and lily extract showed the most significant effect.

[0041] Pathological observation of mouse lung tissue like Figure 5 As shown, the respiratory tract of the lungs includes structures such as bronchioles, respiratory bronchioles, alveolar ducts, alveolar sacs, and alveoli. Under light microscopy, the alveolar structures of mice in the unstimulated NC group were intact, with thin alveolar walls, no thickening, and clear outlines, showing no obvious lesions. In contrast, the lung tissue of mice in the ammonia-induced coughing MC group showed significant capillary congestion, inflammatory response, neutrophil retention and aggregation, alveolar structural destruction or consolidation, and thickening of the alveolar septa. After administration, the CMP and CC groups showed reduced inflammatory cell infiltration, clearer alveolar cavity outlines, thinner alveolar walls, and reduced pulmonary edema and consolidation. The CC+CMP group showed little inflammatory cell infiltration, clear alveolar cavity outlines, normal alveolar walls, and almost no alveolar tissue edema or collapse. Therefore, it can be concluded that water-soluble Poria cocos polysaccharide, lily extract, and the combination of water-soluble Poria cocos polysaccharide and lily extract can effectively alleviate alveolar tissue damage, pulmonary capillary congestion, inflammatory cell retention and aggregation in mice caused by ammonia stimulation. Among them, the water-soluble Poria cocos polysaccharide and lily extract group showed the most significant effect.

[0042] Animal models: Spleen deficiency with dampness (high-fat, high-humidity diet + cold and damp environment) or dampness obstructing the middle jiao (middle burner) model. Dosage regimen: Low / medium / high dose groups (50, 150, 450 mg / kg), administered by gavage for 14 consecutive days. Testing indicators: Macroscopic indicators: urine output, weight change, loose stool score, degree of edema Biochemical indicators: serum SOD / MDA (oxidative stress), Na+ + / K + osmotic pressure Core data from the dehumidification experiment using water-soluble Poria cocos polysaccharide (n=10, x±s) Data Explanation: 1. Statistical method: One-way ANOVA, (Model group vs. blank group), △P<0.05, △△P<0.01 (drug-treated group vs. model group); 2. Dosage groups: Three dosage groups of water-soluble Poria cocos polysaccharide + lily extract (the ratio of water-soluble Poria cocos polysaccharide to lily extract is 1:1): water-soluble Poria cocos polysaccharide group (150mg) and water-soluble lily extract group (150mg). 3. Modeling method: The high-fat and high-moisture diet combined with a cold and humid environment was used to establish the model for 14 days. The drug treatment group was continuously administered the drug by gavage for 14 days.

[0043] Table 1

[0044] As shown in Table 1, the combination of medium- and high-dose water-soluble Poria cocos polysaccharide and lily extract significantly improved the body weight loss and loose stools in the dampness-induced model animals, increased urine output, enhanced antioxidant capacity (increased SOD and decreased MDA), and upregulated the expression of renal aquaporin AQP2, demonstrating a dampness-removing effect. The water-soluble Poria cocos polysaccharide group also showed a significant effect in improving dampness, but its effect was weaker than that of the medium-dose group of the water-soluble Poria cocos polysaccharide + lily extract combination, and only slightly higher than that of the low-dose group of the combination group; at the same time, the improvement effect of the lily extract group alone was not significant, indicating that the combination of the two has a significant enhancing effect.

[0045] For any points not covered above, existing technologies shall apply.

[0046] Although specific embodiments of the present invention have been described in detail by way of examples, those skilled in the art should understand that the above examples are for illustrative purposes only and are not intended to limit the scope of the invention. Those skilled in the art can make various modifications or additions to the described specific embodiments or use similar methods to replace them, without departing from the direction of the invention or exceeding the scope defined by the appended claims. Those skilled in the art should understand that any modifications, equivalent substitutions, improvements, etc., made to the above embodiments based on the technical essence of the present invention should be included within the protection scope of the present invention.

Claims

1. A lung-moistening and dampness-reducing medicinal and edible composition containing Poria cocos polysaccharides, characterized in that, The active ingredients of the composition are composed of the following raw materials in parts by weight: water-soluble Poria cocos polysaccharide: 10-25 parts, lily extract: 4-10 parts.

2. The lung-moistening and dampness-reducing composition containing Poria cocos polysaccharides as described in claim 1, characterized in that, The preparation of water-soluble Poria cocos polysaccharide is as follows: Poria cocos powder is added to ethanol and stirred. Then NaOH is added for alkalization, followed by the addition of an etherifying agent and heating for etherification. The pH is adjusted to 6-7 with glacial acetic acid. The water-soluble Poria cocos polysaccharide sample is washed with ethanol, dried in the sun until its moisture content is less than 7%, and sieved through a 60-100 mesh sieve.

3. The lung-moistening and dampness-reducing composition containing Poria cocos polysaccharides as described in claim 2, characterized in that, The degree of substitution of water-soluble Poria cocos polysaccharide was determined by copper salt complexometric titration, with an average degree of substitution of 0.6 ± 0.

05.

4. The lung-moistening and dampness-reducing composition containing Poria cocos polysaccharides as described in claim 2, characterized in that, The mass-to-volume ratio of Poria cocos powder to ethanol is 60-100g: 300-500mL; the mass ratio of added NaOH, etherifying agent to Poria cocos powder is 18-30: 36-60: 60-100.

5. The lung-moistening and dampness-reducing composition containing Poria cocos polysaccharides as described in claim 1, characterized in that, The preparation method of lily extract specifically includes the following steps: Lily powder was dissolved in ethanol and extracted using ultrasonic extraction. After completion, centrifuge at room temperature and collect the supernatant, which is the lily extract. The lily extract was concentrated to obtain lily extract concentrate; The concentrated lily extract was freeze-dried to obtain crude lily extract. After enzymatic hydrolysis of crude lily extract, centrifugation was performed, and the supernatant was collected. Sevage reagent was added, and the mixture was shaken, centrifuged, and the supernatant was collected. This process was repeated until no protein layer was observed. The final supernatant was then freeze-dried in a freeze dryer to obtain lily extract.

6. The use of the lung-moistening and dampness-reducing composition containing Poria cocos polysaccharide as described in claim 1 in the preparation of health foods or beverages with lung-moistening, dampness-reducing, lung function-improving, and immune-regulating functions.

7. The use of the lung-moistening and dampness-reducing composition containing Poria cocos polysaccharide as described in claim 1 in the preparation of a drug for moistening the lungs, reducing dampness, improving lung function, and regulating immunity.

8. The use as described in claim 7, characterized in that, The food-medicine homology composition can be prepared into any suitable oral drug formulation by adding excipients as needed.

9. The use as described in claim 8, characterized in that, The oral dosage forms of the drug include granules, tablets, capsules, blister packs, effervescent tablets, powders, oral liquids, and pills.

10. The use as described in claim 8, characterized in that, The excipients are pharmaceutically acceptable.

Images